Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: a systematic literature review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: a systematic literature review
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume -, Issue -, Pages 102652
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.ctrv.2023.102652
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
- (2023) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
- (2022) Sumanta K. Pal et al. EUROPEAN UROLOGY
- Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
- (2022) Andrew Warren Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment
- (2022) HIDEKAZU TACHIBANA et al. ANTICANCER RESEARCH
- Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
- (2022) Giandomenico Roviello et al. Cancer Medicine
- Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
- (2022) Yuanquan Yang et al. Cancer Medicine
- Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
- (2022) E. Grande et al. ESMO Open
- Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).
- (2022) Sarmad Sadeghi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).
- (2022) Neil J. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- 1453P Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
- (2022) D.F. McDermott et al. ANNALS OF ONCOLOGY
- A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
- (2022) Giuseppe Procopio et al. TUMORI
- Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO)
- (2021) Daniele Santini et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2021) Chun Loo Gan et al. Cancer Medicine
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
- (2021) Thomas Powles et al. EUROPEAN UROLOGY
- Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).
- (2021) Florence Marteau et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
- (2021) Simon Chowdhury et al. Clinical Genitourinary Cancer
- Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
- (2021) J. Connor Wells et al. Clinical Genitourinary Cancer
- Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies
- (2021) Andrew J. Wiele et al. ONCOLOGIST
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
- (2021) J. Randall Patrinely et al. JAMA Oncology
- A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
- (2021) Giuseppe Procopio et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
- (2021) Elizabeth R Kessler et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
- (2021) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
- (2021) TAIGO KATO et al. ANTICANCER RESEARCH
- 349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3
- (2021) Vijay Kasturi et al. Journal for ImmunoTherapy of Cancer
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
- (2020) Chun Loo Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
- (2020) Igor Stukalin et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
- (2020) Min Hwa Shin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
- (2020) Enrique Grande et al. JOURNAL OF CLINICAL ONCOLOGY
- A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.
- (2020) Mototsugu Oya et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
- (2020) Bradley A. McGregor et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
- (2020) Roberto Iacovelli et al. Targeted Oncology
- 718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
- (2020) T.B. Powles et al. ANNALS OF ONCOLOGY
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
- (2020) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
- (2019) Austin Kalirai et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
- (2019) Marie Auvray et al. EUROPEAN JOURNAL OF CANCER
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
- (2019) A.Y. Shah et al. EUROPEAN JOURNAL OF CANCER
- First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium
- (2019) Shaan Dudani et al. EUROPEAN UROLOGY
- Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
- (2019) Xiting Cao et al. Clinical Genitourinary Cancer
- Renal cell carcinoma treatment after first-line combinations
- (2019) Camillo Porta et al. LANCET ONCOLOGY
- Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
- (2019) Moshe C Ornstein et al. LANCET ONCOLOGY
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
- (2018) Pedro Coelho Barata et al. BRITISH JOURNAL OF CANCER
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
- (2018) Dylan J. Martini et al. Cancer Immunology Research
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Thomas Powles et al. BRITISH JOURNAL OF CANCER
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
- (2017) James Xunhai Xu et al. ONCOLOGIST
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
- (2016) R. Nadal et al. ANNALS OF ONCOLOGY
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
- (2015) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now